Close Search


Enter keywords

Related results

Meet the Innovators Behind immunAware

Originating from the Laboratory of Experimental Immunology at the University of Copenhagen, the minds behind immunAware draws on decades of meticulous research and innovation, focusing on producing superior MHC molecules, developing related assays, collecting data, and providing exceptional services.

Dr. Søren Buus
MD, PhD, founding partner
Embarked on his lifelong exploration of peptide-MHC interactions in the early 1980s when this interaction was still enigmatic. He provided functional and eventually biochemical evidence that peptides specifically interact with their corresponding MHC restriction elements. Dr. Buus pioneered the mapping of the peptide-binding specificity of all human MHC molecules, leading to the inception of the “human MHC project.” His systematic generation of MHC molecules, assays, and data significantly contributed to the development of the NetMHCpan suite of peptide-MHC class I and II predictors.
Dr. Anette Stryhn
MS, PhD, founding partner
Joined the Buus laboratory in the early 1990s. Her groundbreaking work demonstrated that a few biochemically purified peptide-MHC complexes are sufficient to stimulate a peptide-specific, MHC-restricted T cell response. She developed a highly efficient “positional scanning combinatorial peptide library” (PSCPL) approach to experimentally address the peptide-binding specificity of any MHC class I molecule. Dr. Stryhn also pioneered the “easYmer” technology, enabling the efficient and large-scale production of peptide-MHC class I complexes. Her research involved generating peptide-MHC class I and II complexes, which were instrumental in tetramer-guided CD8+ and CD4+ T cell epitope discovery.
Dr. Thomas Østerbye
MS, PhD, founding partner
Joined the Buus lab in the late 2000s, played a vital role in generating peptide-MHC class II tetramers. He coordinated EU-funded (FP7 and Horizon 2020) projects aimed at providing a high-density peptide microarray platform, which he utilized to investigate the peptide-binding specificity of MHC class II molecules. To improve the identification of immunogenic peptides, he developed a large-scale, real-time, non-radioactive peptide-MHC class I dissociation assay.